What innovative methodologies applicable to small cohorts and rare outcomes can better ensure the success of clinical and implementation studies in the rare diseases affecting heart, lung, blood, and sleep?

Are the current methodologies for clinical trials still the best practices for conducting efficient clinical trials?

During this period of diminishing Federal resources and funding, what novel methods can be employed to effectively conduct clinical trials that address existing and emerging medical and public health issues?

The use of win-ratio and other new statistical methods to analyze endpoints in new and existing clinical trials.